 |
 |
 |
| 24小時(shí)熱門(mén)版塊排行榜 |
- >論壇更新日志 (6360)
- >導(dǎo)師招生 (1286)
- >考研 (1179)
- >基金申請(qǐng) (530)
- >文獻(xiàn)求助 (503)
- >蟲(chóng)友互識(shí) (321)
- >考博 (279)
- >休閑灌水 (192)
- >碩博家園 (160)
- >論文投稿 (151)
- >招聘信息布告欄 (104)
- >博后之家 (88)
- >公派出國(guó) (47)
- >論文道賀祈福 (35)
- >綠色求助(高懸賞) (31)
- >SciFinder/Reaxys (30)
 |
 |
 |
||
 |
 |
 |
 |
 |
| 3 | 1/1 | 返回列表 |
| 查看: 671 | 回復(fù): 2 | |||
ienjoysun銀蟲(chóng) (著名寫(xiě)手)
|
[交流]
GSK issues recall after Irish API plant slammed by US FDA Warning Letter 已有2人參與
|
|
GSK issues recall after Irish API plant slammed by US FDA Warning Letter By Dan Stanton+ 01-Apr-2014 GlaxoSmithKline has issued a recall of its antidepressant drug Paxil after receiving a US FDA Warning Letter for failing to fully investigate contamination issues at an Irish API plant. The US Food and Drug Administration (FDA) inspected the Currabinny, Cork active pharmaceutical ingredient facility in October 2013, and identified a number of deviations from current good manufacturing practice (cGMP). The Letter , received March 18, noted the firm had failed to fully investigate critical deviations after equipment used to make batches of APIs were found to be “contaminated with material from [its] pharmaceutical waste tank, which contained APIs, intermediates, and solvents.” Whilst GSK was aware of the contamination risk in January 2012 and completed risk assessments to determine the impact on the quality of its product, some potentially contaminated batches were still distributed. A statement sent to in-Pharmatechnolgist.com from a GSK spokesman said: "We are currently reviewing the content of the FDA letter to assess the concerns raised. In the meantime, we have proposed a Class 3 recall – that is a recall from wholesalers - of certain batches of Paxil/Seroxat containing the active ingredient Paroxetine supplied by the Cork site, that are within the scope of the Warning Letter. Paxil is a selective serotonin re-uptake inhibitor used to treat amongst other things major depression, obsessive-compulsive disorder, panic disorder, and social anxiety. The drug has been off-patent since 2003. "A medical assessment concluded that that there is no risk of harm to patients by taking Paxil/Seroxat manufactured from the implicated batches of paroxetine API. However GSK has acknowledged some procedural issues raised by the FDA about the testing done to the support the release of product," GSK added. Quality Concerns The Letter further questioned GSK’s view on quality after the FDA’s investigator was informed the firm did not wish to “escalate” the deviation by informing customers. “We are concerned that your firm does not consider the entry of pharmaceutical waste streams into your manufacturing process a significant deviation with a potential quality impact,” the FDA noted. The agency also pulled GSK up on its failure to investigate and document out-of-specification results, and the failure to demonstrate that its manufacturing process could reproducibly manufacture an API meeting its predetermined quality attributes. “Demonstrating suitability of equipment used in the manufacturing process is a fundamental element of establishing the state of control of your process. Because of these equipment suitability deficiencies, we are concerned that your firm has not adequately demonstrated an ability to consistently and reproducibly manufacture [the product].” According to GSK’s website, the firm has been manufacturing APIs from the site since 1975 and is described as “a strategic global new product introduction site within GSK’s manufacturing network.” Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions |
回復(fù)此樓» 猜你喜歡
SPguide®：小鼠體內(nèi)脾臟轉(zhuǎn)染的一鍵解決方案
已經(jīng)有0人回復(fù)
-
高效肺靶向RNA轉(zhuǎn)染，加速肺部RNA藥物開(kāi)發(fā)
已經(jīng)有2人回復(fù)
-
藥理學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有106人回復(fù)
-
二糖的糖脂，合成后sephadex LH-20分離不出來(lái)，求助
已經(jīng)有1人回復(fù)
-
南方醫(yī)科大學(xué)珠江醫(yī)院肖計(jì)生課題組招收博士生 （2026年入學(xué)）
已經(jīng)有2人回復(fù)
-
349藥學(xué)專(zhuān)碩105500求調(diào)劑
已經(jīng)有0人回復(fù)
-
求調(diào)劑
已經(jīng)有1人回復(fù)
-
298求調(diào)劑一志愿中海洋
已經(jīng)有3人回復(fù)
-
藥學(xué)調(diào)劑申請(qǐng)自薦信，一志愿中南大學(xué)
已經(jīng)有1人回復(fù)
-
藥學(xué)349專(zhuān)碩求調(diào)劑
已經(jīng)有1人回復(fù)
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復(fù)
| 謝謝分享 |
2樓2014-04-04 16:05:38
1949stone
榮譽(yù)版主 (知名作家)
海納百川
- 應(yīng)助: 95 (初中生)
- 貴賓: 2.38
- 金幣: 2627.9
- 散金: 3394
- 紅花: 177
- 沙發(fā): 8
- 帖子: 9830
- 在線: 2692.8小時(shí)
- 蟲(chóng)號(hào): 765987
- 注冊(cè): 2009-05-08
- 性別: GG
- 專(zhuān)業(yè): 藥物分析
- 管轄: 分子生物
3樓2014-04-04 16:11:24
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 ienjoysun 的主題更新
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 0703化學(xué)調(diào)劑 +4 | 18889395102 2026-03-18 | 4/200 |
|
|---|---|---|---|---|
|
|
[考研] 材料與化工求調(diào)劑 +7 | 為學(xué)666 2026-03-16 | 7/350 |
|
|
|
[考研] 一志愿 西北大學(xué) ，070300化學(xué)學(xué)碩，總分287，雙非一本，求調(diào)劑。 +3 | 晨昏線與星海 2026-03-19 | 3/150 |
|
|
|
[考研] 一志愿中海洋材料工程專(zhuān)碩330分求調(diào)劑 +7 | 小材化本科 2026-03-18 | 7/350 |
|
|
[考研] 311求調(diào)劑 +4 | 冬十三 2026-03-18 | 4/200 |
|
|
|
[考研] 304求調(diào)劑 +12 | 小熊joy 2026-03-14 | 13/650 |
|
|
|
[考研] 299求調(diào)劑 +5 | △小透明* 2026-03-17 | 5/250 |
|
|
|
[考研] 0703化學(xué)求調(diào)劑 總分331 +3 | ZY-05 2026-03-13 | 3/150 |
|
|
|
[考研] 301求調(diào)劑 +9 | yy要上岸呀 2026-03-17 | 9/450 |
|
|
|
[考研] 278求調(diào)劑 +5 | 煙火先于春 2026-03-17 | 5/250 |
|
|
|
[考研] 293求調(diào)劑 +11 | zjl的號(hào) 2026-03-16 | 16/800 |
|
|
|
[考研] 296求調(diào)劑 +5 | 大口吃飯 身體健 2026-03-13 | 5/250 |
|
|
|
[考研] 302求調(diào)劑 +4 | 小賈同學(xué)123 2026-03-15 | 8/400 |
|
|
|
[考研] 0854控制工程 359求調(diào)劑 可跨專(zhuān)業(yè) +3 | 626776879 2026-03-14 | 9/450 |
|
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學(xué)獎(jiǎng)覬?/a> 2026-03-15 | 7/350 |
|
|
|
[考研] 一志愿211 0703方向310分求調(diào)劑 +3 | 努力奮斗112 2026-03-15 | 3/150 |
|
|
|
[考研] 277材料科學(xué)與工程080500求調(diào)劑 +3 | 自由煎餅果子 2026-03-16 | 3/150 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 290分有科研經(jīng)歷，論文在投 +7 | 膩膩gk 2026-03-14 | 7/350 |
|
|
|
[考研] 311求調(diào)劑 +3 | 冬十三 2026-03-13 | 3/150 |
|
|
|
[考研] 295求調(diào)劑 +3 | 小匕仔汁 2026-03-12 | 3/150 |
|